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Response from CLOTHES Trial team 
Dear Editor, 
We would like to respond to the recent letter by Wüthrich and colleagues.[1]    
As Wüthrich et al. have used silk garments within their hospital clinic for many decades it is 
unsurprising they so strongly believe in the value of these products. Unfortunately, the extent of 
their investment has seemingly left them unable to countenance information that does not accord 
with their own experience. Indeed, their correspondence aptly illustrates the need to scientifically 
evaluate the efficacy of treatments in adequately-powered randomised controlled trials, conducted 
from a position of equipoise, and therefore minimise the potential for conflicts and bias.  
Wüthrich and colleagues, seemingly unfamiliar with commonly operated Open Access models used 
by journals, make reference to PLOS Medicines publishing fees. For their benefit, let us firstly state 
that PLOS Medicine, a distinguished journal, accepts just 3% of submitted papers. Secondly, 
following acceptance article authors can pay fees to the journal to allow the content to be accessed 
by the public for free. This is not the same as paying for a paper to be accepted. 
The information that Wüthrich and colleagues claim to be missing from the PLOS Medicine paper, is 
in fact all available.  The authors state that the results of CLOTHES was contrary to previous studies. 
Prior to CLOTHES, the evidence on silk clothing for eczema was considered low quality and 
insufficient to guide practice when evaluated in three systematic reviews.[2-4] The limited evidence 
prompted the UK National Institute for Health Research to commission the CLOTHES study to inform 
practice.[5] The authors then state that our eligibility criteria meant that some with mild eczema 
were included. Our eligibility criteria were pre-defined in the trial protocol which was publicly 
available before recruitment started. They were never challenged during peer-review of the protocol 
or after publication.[6] Our choice of eligibility criteria did not bias the results or change the study 
conclusions. Sensitivity analysis that explored the impact of different eczema severities at baseline 
found no evidence to suggest that those with more severe disease were more likely to benefit from 
silk garments. The baseline severity information requested by Wüthrich et al is available in Table 2, 
and implications of enrolling more children with mild disease than expected were explained in the 
discussion.  
The authors suggest that adherence during the trial does not reflect how silk clothes are used in 
practice. On the contrary, our trial attempted to reflect how the garments would be used in real life. 
Children were asked to wear the garments as often as possible (day and night) for a period of 6 
months. Children wore the garments for a median of 81% of nights and 34% of days. A separate 
analysis showed that there was no evidence of benefit from wearing the clothing more often.  
Our interpretation of the secondary outcome of eczema symptoms is also questioned. It was clear 
from talking to eczema patients before the trial that expectation of benefit from silk clothing was 
high, thus increasing the likelihood of information bias for patient-reported outcomes given the 
intervention allocation was not blinded. The CLOTHES trial was therefore designed as an 
investigator-blind trial, whereby the primary outcome (severity using EASI) was assessed by trained 
and blinded research nurses.  The initial small benefit shown on the POEM symptom scale was not 
sustained. Patient-reported results were fully discussed in our paper and considered when 
presenting the trial conclusions.  
We believe that the CLOTHES trial provides the first high-quality, independent evidence on the use 
of silk clothing for eczema. We hope that these results assist healthcare providers and people with 
eczema in making informed choices. 
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